Published in
Elsevier, The Lancet, 10294(398), p. 27-40, 2021
DOI: 10.1016/s0140-6736(21)00797-2
Links
Tools
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Journal article published in 2021 by
Yelena Y. Janjigian,
Kohei Shitara,
Markus Moehler,
Marcelo Garrido 
,
Pamela Salman,
Lin Shen,
Lucjan Wyrwicz,
Kensei Yamaguchi,
Tomasz Skoczylas,
Arinilda Campos Bragagnoli,
Tianshu Liu,
Michael Schenker,
Patricio Yanez,
Mustapha Tehfe,
Ruben Kowalyszyn
and other authors.
,
Pamela Salman,
Lin Shen,
Lucjan Wyrwicz,
Kensei Yamaguchi,
Tomasz Skoczylas,
Arinilda Campos Bragagnoli,
Tianshu Liu,
Michael Schenker,
Patricio Yanez,
Mustapha Tehfe,
Ruben Kowalyszyn
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 